Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies (Q36145455)

12 August 2017

0 references

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies (English)

1 reference

12 August 2017

8

Razelle Kurzrock

1 reference

12 August 2017

6

Aung Naing

1 reference

12 August 2017

Rajul K Jain

1

1 reference

12 August 2017

J Jack Lee

2

1 reference

12 August 2017

Chaan Ng

3

1 reference

12 August 2017

David Hong

4

1 reference

12 August 2017

Jing Gong

5

1 reference

12 August 2017

Jennifer Wheler

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

11 June 2012

1 reference

Journal of Clinical Oncology

12 August 2017

1 reference

12 August 2017

30

1 reference

12 August 2017

21

1 reference

12 August 2017

2684-2690

1 reference

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

A Regulatory Overview About Rare Diseases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Tumor response evaluation in oncology: current update.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Healthy volunteers and early phases of clinical experimentation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

We should desist using RECIST, at least in GIST.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

The needs of science vs the needs of patients: ethical concerns in cancer clinical trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Ethical issues in the development of new agents

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Dose-response in the treatment of breast cancer: a critical review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Analysis of survival by tumor response.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Phase I clinical trial design in cancer drug development

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Diagnostic plots to reveal functional form for covariates in multiplicative intensity models.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

On the nature and ethics of phase I clinical trials of cancer chemotherapies

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413279

Response rates, survival, and chemotherapy trials

5 December 2018

1 reference

12 December 2020

Reporting results from chemotherapy trials. Does response make a difference in patient survival?

1 reference

12 December 2020

Measuring response in a post-RECIST world: from black and white to shades of grey

1 reference

12 December 2020

1 reference

12 December 2020

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

1 reference

12 December 2020

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2011.36.4752

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22689801

1 reference